Neurocrine Biosciences Revenue, Profits - NBIX Quarterly Income Statement

Add to My Stocks
$117.41 $2.85 (2.37%) NBIX stock closing price Sep 19, 2018 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking Neurocrine Biosciences stock price alone is not sufficient. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. Like any other income statement, the NBIX income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue growth of 36.32% when compared to the same period in the past. Along with Neurocrine Biosciences assets and Neurocrine Biosciences free cash flow, Neurocrine Biosciences profits as shown in profit and loss statement give key insights about the business. The net profit for 2018 Q2 is $-5.91M and the 2018 Q2 revenue is $96.91M.

View and download details of revenue and profits for Neurocrine Biosciences for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Neurocrine Biosciences Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Neurocrine Biosciences Gross Profit
Research & Development Expense36.99M48.94M25.62M22.46M21.86M51.88M22.59M20.94M26.86M23.9M
Selling General & Admin Expense60.92M58.63M56.31M43.87M41.67M28.05M23.68M17.49M14.96M11.95M
Income Before Depreciation Depletion Amortization-1.85M-37.44M11.82M-5.99M-57.26M-79.93M-46.27M-38.43M-41.82M-20.85M
Depreciation Depletion Amortization----------
Non Operating Income3.53M3.13M2.49M2.2M2.05M1.6M1.61M1.54M1.54M1.59M
Interest Expense7.59M7.5M7.43M7.33M4.76M-----
Neurocrine Biosciences Pretax Income
Provision for Income Taxes----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-5.91M-41.82M6.89M-11.13M-59.99M-78.33M-44.66M-36.89M-40.28M-19.26M
Extraordinary Items & Discontinued Operations----------
Neurocrine Biosciences Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS90.1M89.53M92.66M88.33M88.06M87.28M86.87M86.78M86.69M86.5M
Average Shares used to compute Basic EPS90.1M89.53M88.67M88.33M88.06M87.28M86.87M86.78M86.69M86.5M
Income Before Nonrecurring Items-5.91M-41.82M6.89M-11.13M-59.99M-78.33M-44.66M-36.89M-40.28M-19.26M
Income from Nonrecurring Items----------
Neurocrine Biosciences Earnings Per Share Basic Net
Neurocrine Biosciences Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.07-0.470.07-0.13-0.68-0.90-0.51-0.43-0.46-0.22
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Neurocrine Biosciences stock analysis involves checking at least a few of the important things like:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that NBIX stock has a topline or revenue of $96.91M for 2018 Q2 as per this Neurocrine Biosciences revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-5.91M for Neurocrine Biosciences for 2018 Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the NBIX income statement, one can check the Neurocrine Biosciences historical stock prices to check how the price has moved with time.

Neurocrine Biosciences Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield

Other Income Statements - Neurocrine Biosciences, Inc. Industry Peers

Nektar Therapeutics income statement, Pfizer income statement, Sage Therapeutics income statement